Education
About Us
Working with TipRanks
Follow Us
QuidelOrtho (QDEL)
NASDAQ:QDEL
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
>-0.01Last Year’s EPS
-0.07Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 15.05%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted solid revenue growth excluding COVID impacts, improved profitability metrics, and effective cost-saving measures. However, challenges such as declining total revenue, COVID-related declines, and tariff impacts were noted. Despite these challenges, the company is confident in its mitigation strategies and maintains its financial guidance.Company Guidance
During the QuidelOrtho Q1 2025 earnings call, the company provided specific financial guidance and metrics reflecting their performance and strategic outlook. The call highlighted a mid-single-digit revenue growth of 6%, excluding COVID and donor screening, driven by a 7% increase in their labs business and 4% growth in immunohematology. Adjusted EBITDA margin improved by 450 basis points year-over-year, resulting in a 68% increase in adjusted diluted EPS. The company maintained its full-year guidance with expected revenue between $2.6 billion and $2.81 billion, and adjusted EBITDA of $575 million to $615 million. QuidelOrtho aims to offset anticipated tariff impacts of $30 million to $40 million through cost-saving initiatives and strategic mitigations, expecting $50 million in cost savings in the first half of 2025. Additionally, they project COVID revenue of $110 million to $140 million, with strong flu sales contributing to 18% year-over-year growth. The company is also focused on completing the clinical trial for their Savanna respiratory panel, aiming for an FDA submission in the summer, while continuing to expand their global operating footprint and manufacturing capabilities to support business growth.Revenue Growth Excluding COVID and Donor Screening
Achieved mid-single-digit revenue growth of 6% in Q1 2025, driven by strong performance in the labs business, immunohematology, and a robust flu season.
Improved Adjusted EBITDA Margin
Saw a 450 basis point year-over-year improvement in adjusted EBITDA margin, reflecting cost-saving initiatives.
Significant Increase in Adjusted Diluted EPS
Adjusted diluted earnings per share increased by 68% compared to the prior year period.
Lab Business and Geographical Growth
The labs business, comprising 54% of total revenue, grew by 7%. The 'Other' region, including Japan, Asia-Pac, and Latin America, experienced 12% growth.
Cost Savings Initiatives
On track to realize $100 million in annualized cost savings, with $50 million expected in the first half of 2025.
QDEL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
QDEL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $25.85 | $36.46 | +41.04% |
Feb 12, 2025 | $39.94 | $41.65 | +4.28% |
Nov 07, 2024 | $38.85 | $43.75 | +12.61% |
Jul 31, 2024 | $39.29 | $42.00 | +6.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does QuidelOrtho (QDEL) report earnings?
QuidelOrtho (QDEL) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is QuidelOrtho (QDEL) earnings time?
QuidelOrtho (QDEL) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is QDEL EPS forecast?
QDEL EPS forecast for the fiscal quarter 2025 (Q2) is >-0.01.
